Equities research analysts expect Incyte Corporation (NASDAQ:INCY) to report $409.49 million in sales for the current quarter, Zacks reports. Twenty analysts have issued estimates for Incyte’s earnings, with the lowest sales estimate coming in at $374.55 million and the highest estimate coming in at $437.20 million. Incyte reported sales of $326.50 million in the same quarter last year, which indicates a positive year-over-year growth rate of 25.4%. The company is scheduled to report its next quarterly earnings results on Tuesday, February 13th.

On average, analysts expect that Incyte will report full-year sales of $409.49 million for the current fiscal year, with estimates ranging from $1.47 billion to $1.53 billion. For the next fiscal year, analysts expect that the company will post sales of $1.76 billion per share, with estimates ranging from $1.52 billion to $1.96 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Incyte.

Incyte (NASDAQ:INCY) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.11. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The business had revenue of $381.50 million for the quarter, compared to analyst estimates of $360.34 million. During the same quarter last year, the firm posted $0.19 earnings per share. The business’s revenue was up 41.6% compared to the same quarter last year.

A number of research firms have weighed in on INCY. J P Morgan Chase & Co reiterated a “buy” rating and issued a $149.00 target price on shares of Incyte in a research note on Thursday, August 31st. Oppenheimer reiterated a “hold” rating and issued a $135.00 target price on shares of Incyte in a research note on Thursday, August 31st. BMO Capital Markets reiterated an “outperform” rating and issued a $163.00 target price (down previously from $172.00) on shares of Incyte in a research note on Monday, September 11th. Raymond James Financial upgraded Incyte from a “market perform” rating to an “outperform” rating and set a $159.00 target price on the stock in a research note on Monday, September 11th. Finally, Argus reiterated a “buy” rating and issued a $150.00 target price on shares of Incyte in a research note on Wednesday, September 13th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Incyte currently has an average rating of “Buy” and a consensus target price of $143.84.

In other news, insider David W. Gryska sold 3,915 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total transaction of $413,541.45. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Herve Hoppenot sold 70,502 shares of the firm’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $119.45, for a total value of $8,421,463.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 103,620 shares of company stock worth $11,903,297. Insiders own 17.70% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Wetherby Asset Management Inc. boosted its position in Incyte by 1.4% during the second quarter. Wetherby Asset Management Inc. now owns 1,672 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 23 shares in the last quarter. Nordea Investment Management AB boosted its position in Incyte by 0.8% during the second quarter. Nordea Investment Management AB now owns 8,179 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 67 shares in the last quarter. IFP Advisors Inc boosted its position in Incyte by 9.9% during the second quarter. IFP Advisors Inc now owns 1,146 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 103 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Incyte by 13.8% during the second quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 108 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its position in Incyte by 2.8% during the second quarter. Teacher Retirement System of Texas now owns 4,855 shares of the biopharmaceutical company’s stock valued at $611,000 after purchasing an additional 133 shares in the last quarter. 90.86% of the stock is currently owned by institutional investors.

Shares of Incyte (NASDAQ:INCY) opened at $95.97 on Friday. The company has a quick ratio of 4.81, a current ratio of 4.82 and a debt-to-equity ratio of 0.01. Incyte has a 52 week low of $92.91 and a 52 week high of $153.15.

TRADEMARK VIOLATION WARNING: This news story was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/12/15/brokerages-anticipate-incyte-corporation-incy-will-post-quarterly-sales-of-409-49-million.html.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Get a free copy of the Zacks research report on Incyte (INCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.